Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1770 participants.

Also called NCT05192941

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,770 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05192941
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Bulgaria, Czechia, Estonia, France, Germany, Latvia, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05192941. Randomized; quadruple masking; primary purpose treatment. Start 2022-04-08 (actual); primary completion 2024-06-11 (actual). Results posted on 2026-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Acronym
V-DIFFERENCE
Condition
Hypercholesterolemia
Intervention (Drug)
Inclisiran Sodium
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05192941
Content hash
90a6763227fab968f7df273a5b5daac5c0c1161ffe049bc222ffc00b04c49200